First Capital Advisors Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

First Capital Advisors Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$17.3K	Buy	+200	New	+$18.8K	0.01%	448
2018 Q2	–	Sell	-61	Closed	-$5K	–	241
2018 Q1	$5K	Buy	+61	New	+$5.24K	﹤0.01%	628

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

First Capital Advisors Group's BMRN Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2023: 200 shares worth $17.3K. The stake represents 0.01% of the portfolio and ranks #448 among its holdings. This is a return to the name: First Capital Advisors Group previously reported a position in BMRN as recently as Q1 2018.

First Capital Advisors Group first reported a position in BMRN in Q1 2018 and has held it in 2 quarters since. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

First Capital Advisors Group held 200 shares of BioMarin Pharmaceuticals worth $17.3K as of Q2 2023.
BioMarin Pharmaceuticals was a new First Capital Advisors Group position in Q2 2023.
BioMarin Pharmaceuticals made up 0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #448 holding.
First Capital Advisors Group first reported a position in BioMarin Pharmaceuticals in Q1 2018 and has held it in 2 quarters since.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.